Greenberg DD, et al. - Investigators assessed 17 patients with giant cell tumors (GCT) to analyze the consequences of an alternative intraoperative local delivery (adjuvant therapies are usually applied locally after curettage of giant cell tumors) of bisphosphonates (BP) on giant cell tumors (GCT). Patients underwent prolonged surgical curettage procedures involving high-speed burring, traditional adjuvant therapy, and application of BP-loaded polymethylmethacrylate bone cement. They observed no cases of pulmonary metastases. Local recurrence (LR) rate was 5.9% with one LR during the follow-up period, which ranged from 1 to 12 years. No systemic/localized avascular necrosis or atypical fractures associated with BPs was recorded, so they suggested this method was safe and tolerable and might reduce LR.